Cumulative incidences of hypogonadism, hypertension, and dyslipidaemia in patients with stage I seminoma treated with a risk‑adapted strategy:: a Spanish single‑centre retrospective analysis

Jose C. Tapia Tapia; Javier Gavira; Georgia Anguera Palacios; Sofia Sanchez del Río; Alejandra Romano; Freya Bosma Ainaud; Alejandra Molina Pérez; Judit Sanz Beltran; Cristina Martin Lorente; Pablo Maroto Rey; Fernando Algaba

Ayuda

Cumulative incidences of hypogonadism, hypertension, and dyslipidaemia in patients with stage I seminoma treated with a risk‑adapted strategy:: a Spanish single‑centre retrospective analysis

Jose C. Tapia ^[1] ; Javier Gavira ^[1] ; Georgia Anguera ^[1] ; Sofia Sanchez ^[1] ; Alejandra Romano ^[1] ; Freya Bosma ^[1] ; Alejandra Molina ^[1] ; Judit Sanz Beltran ^[1] ; Cristina Martin Lorente ^[1] ; Pablo Maroto ^[1] ; Fernando Algaba ^[2]
1. [1] Hospital de la Santa Creu i Sant Pau
  
  Hospital de la Santa Creu i Sant Pau
  
  Barcelona, España
2. [2] Pathology Department, Fundació Puigvert, Cartagena 340, 08025 Barcelona, Spain
Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 7, 2024, págs. 1798-1803
Idioma: inglés
Texto completo no disponible (Saber más ...)
Resumen
- Purpose To describe the incidences of hypogonadism, hypertension, and dyslipidaemia in patients with stage 1 seminoma (S1S) testicular cancer (TC) treated with a risk-adapted strategy.
  
  Methods A retrospective analysis from 2000 to 2020 was conducted. Active surveillance (AS), carboplatin one cycle, and carboplatin two cycles were ofered according to risk factors. Cumulative incidences and relapse-free survival (RFS) were estimated.
  
  Results Of the 145 patients, 8 (5.4%) were excluded due to bilateral TC or hypogonadism at diagnosis. Median follow-up time was 8.2 years. Eighty-four, 30, and 33 patients were treated with AS, carboplatin one cycle, and carboplatin two cycles, respectively. In the overall population, the 5-year and 10-year cumulative incidences were 1.6% and 5.3% for hypogonadism; 2.0% and 8.6% for hypertension; and 12.4% and 25.1% for dyslipidaemia. No statistically signifcant diferences were found in the incidences among the three adjuvant strategies. Five-year and 10-year RFS were 85.9% and 83.3% for AS; 92.4% and 84.0% for carboplatin one cycle; and 96.7% at both times for carboplatin two cycles.
  
  Conclusion There were no statistically diferences in cumulative incidences of hypogonadism, hypertension, and dyslipidaemia in S1S patients treated with a risk-adapted strategy